ArticleCancer medicine2026
Life's Essential 8 and the Risk of Overall and Specific-Site Cancer Types: A Large-Scale Prospective Cohort Study.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Life's Essential 8 and the Risk of Overall and Specific-Site Cancer Types: A Large-Scale Prospective Cohort Study.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Life's Essential 8 (LE8) framework, designed to prevent cardiovascular disease, is also linked to cancer risk, but the direct association between LE8 adherence and cancer incidence remains underexplored. Each LE8 component may affect cancer risk differently across organ systems, warranting further investigation into these relationships.
methodsThis prospective cohort study utilized data from the Kailuan Study, comprising 94,239 participants from Tangshan, China. LE8 scores were calculated based on lifestyle and physiological measures, including diet, physical activity, and biomarkers such as blood glucose and cholesterol levels. Incident cancer cases were monitored through biennial health assessments and verified through multiple data sources until December 31, 2022. Cox proportional hazards models and competing risk models adjusted for confounders like age, sex, and lifestyle factors were used to analyze the impact of LE8 as well as each LE8 component on various cancer types.
resultsDuring a median follow-up of 14.99 years, 5124 incident cancer cases were identified. Compared to poor LE8 adherence, intermediate and ideal adherence groups showed a 13% (HR = 0.87; 95% CI: 0.80-0.96) and 26% (HR = 0.74; 95% CI: 0.65-0.85) decrease in overall cancer incidence, respectively. Improvements in LE8 scores were linked to reduced risks of specific cancers: lung (9%), breast (12%), kidney (18%), colorectal (7%), and endometrial (31%), with hazard ratios of 0.91, 0.88, 0.82, 0.93, and 0.69, respectively. Ideal blood pressure and non-smoking were protective against cancer, while ideal body weight increased the risk. Non-smoking reduced lung and kidney cancer risk, while ideal BMI had mixed effects.
conclusionsOur findings support the LE8 framework as an effective tool for cancer prevention, with higher adherence linked to lower cancer incidence across various types. The results advocate for the integration of LE8 into broader public health and clinical strategies.
trial registrationKailuan study, ChiCTR-TNRC-11001489. Registered August 24, 2011-Retrospectively registered, http://www.chictr.org.cn/showprojen.aspx?proj=8050.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.